Christopher Rowland, The Washington Post; Trump administration sues drugmaker Gilead Sciences over patent on Truvada for HIV prevention
"The Trump administration took the rare step Wednesday of filing a patent
infringement lawsuit against pharmaceutical manufacturer Gilead
Sciences over sales of Truvada for HIV prevention, a crucial therapy
invented and patented by Centers for Disease Control researchers."
The Ebook version of my Bloomsbury book "Ethics, Information, and Technology" will be published on December 11, 2025 and the Hardback and Paperback versions will be available on January 8, 2026. The book includes chapters on IP, OM, AI, and other emerging technologies. Preorders are available via Amazon and this Bloomsbury webpage: https://www.bloomsbury.com/us/ethics-information-and-technology-9781440856662/
Showing posts with label Gilead Sciences Inc.. Show all posts
Showing posts with label Gilead Sciences Inc.. Show all posts
Thursday, November 7, 2019
Saturday, March 26, 2016
Reuters; Gilead ordered to pay Merck $200 million in hepatitis C drug patent dispute; Reuters, 3/24/16
Reuters; Gilead ordered to pay Merck $200 million in hepatitis C drug patent dispute:
"A federal jury on Thursday ordered Gilead Sciences Inc (GILD.O) to pay Merck & Co (MRK.N) $200 million in damages for infringing two Merck patents related to a lucrative cure for hepatitis C. The damages award is far less than the $2 billion Merck had demanded. On Tuesday, the same jury in San Jose, California, upheld the validity of the patents, which lie at the heart of the dispute over Gilead's blockbuster drugs Sovaldi and Harvoni. Together the medicines had more than $20 billion in U.S. sales in 2014 and 2015."
Subscribe to:
Posts (Atom)